Drug Patents Expiring in 2041
1. Acthar Gel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752199 | MALLINCKRODT ARD | Methods of modulating pericytes |
Feb, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 15, 2017 |
Drugs and Companies using CORTICOTROPIN ingredient
Treatment: Treatment of ophthalmic diseases with corticotropin by promoting new vessel formation wherein vcam-1 expression and angiopoetin-2 expression is increased after the administering
Dosage: INJECTABLE;INJECTION
ACTHAR GEL family patents
2. Airduo Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11173259 (Pediatric) | TEVA PHARM | Drug delivery device with electronics and power management |
Jan, 2041
(16 years from now) | |
| US11266796 | TEVA PHARM | Inhalation device with integrated electronics |
Feb, 2041
(16 years from now) | |
|
US11266796 (Pediatric) | TEVA PHARM | Inhalation device with integrated electronics |
Aug, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
3. Armonair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11173259 (Pediatric) | TEVA PHARM | Drug delivery device with electronics and power management |
Jan, 2041
(16 years from now) | |
| US11266796 | TEVA PHARM | Inhalation device with integrated electronics |
Feb, 2041
(16 years from now) | |
|
US11266796 (Pediatric) | TEVA PHARM | Inhalation device with integrated electronics |
Aug, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
4. Austedo Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311488 | TEVA | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Jun, 2041
(17 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: A method of treating huntington's chorea
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR family patents
5. Bylvay patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583539 | ALBIREO | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
| New Indication(I-918) | Jun 13, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)
Dosage: CAPSULE;ORAL; CAPSULE, PELLETS;ORAL
BYLVAY family patents
6. Dapzura Rt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173189 | BAXTER HLTHCARE CORP | Daptomycin formulations containing a combination of sorbitol and mannitol |
Mar, 2041
(16 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 25 January, 2022
Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol
Dosage: POWDER;INTRAVENOUS
DAPZURA RT family patents
7. Eligard Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 24 July, 2002
Treatment: NA
Dosage: POWDER;SUBCUTANEOUS
ELIGARD KIT family patents
8. Epidiolex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11406623 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(16 years from now) | |
| US11160795 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| M(M-270) | Oct 20, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| New Patient Population(NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of seizures associated with tuberous sclerosis complex in patients taking everolimus
Dosage: SOLUTION;ORAL
EPIDIOLEX family patents
9. Exparel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11819575 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11033495 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11357727 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11311486 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11278494 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11304904 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11819574 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11452691 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11179336 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| US11426348 | PACIRA PHARMS INC | Compositions of bupivacaine multivesicular liposomes |
Jan, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
| New Indication(I-771) | Apr 06, 2021 |
| New Product(NP) | Oct 28, 2014 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: Method of treating pain, for example, treating postsurgical pain via infiltration for local analgesia or via interscalene brachial plexus nerve block for regional analgesia; Method of providing postsu...
Dosage: INJECTABLE, LIPOSOMAL;INJECTION
EXPAREL family patents
10. Fabhalta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11603363 | NOVARTIS | Crystalline form of LNP023 |
May, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: NA
Dosage: CAPSULE;ORAL
FABHALTA family patents
11. Fensolvi Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-829) | May 01, 2023 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 01 May, 2020
Treatment: NA
Dosage: POWDER;SUBCUTANEOUS
FENSOLVI KIT family patents
12. Hetlioz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759446 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Feb, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: CAPSULE;ORAL
HETLIOZ family patents
13. Hetlioz Lq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11759446 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Feb, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
| New Product(NP) | Dec 01, 2023 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: SUSPENSION;ORAL
HETLIOZ LQ family patents
14. Invega Hafyera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11666697 | JANSSEN PHARMS | Methods for ensuring resuspension of paliperidone palmitate formulations |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
| New Product(NP) | May 18, 2018 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 30 August, 2021
Treatment: Treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose; Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks ...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA HAFYERA family patents
15. Lybalvi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11707466 | ALKERMES INC | Immediate release multilayer tablet |
Nov, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: TABLET;ORAL
LYBALVI family patents
16. Lyvispah patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11491125 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(17 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases
Dosage: GRANULES;ORAL
LYVISPAH family patents
17. Multrys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
MULTRYS family patents
18. Norliqva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
| US11458095 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
| US11723866 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina; Norliqva is indicated for the symptomatic treatment of chronic stable angina
Dosage: SOLUTION;ORAL
NORLIQVA family patents
19. Opzelura patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11602536 | INCYTE CORP | Topical treatment of vitiligo by a JAK inhibitor |
May, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: For the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older, in the absence of laser or phototherapy, wherein the vitiligo affects at least one of the ...
Dosage: CREAM;TOPICAL
OPZELURA family patents
20. Paxlovid (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11351149 | PFIZER | Nitrile-containing antiviral compounds |
Aug, 2041
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541034 | PFIZER | Nitrile-containing antiviral compounds |
Oct, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using NIRMATRELVIR; RITONAVIR ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Treatment of mild-to-moderate coronavirus disease 2019 (covid-19) in adults who are at high risk for progression to severe covid-19, including hospitalization or death
Dosage: TABLET;ORAL
PAXLOVID (COPACKAGED) family patents
21. Phyrago patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324745 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11202778 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11298356 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
Drugs and Companies using DASATINIB ingredient
Market Authorisation Date: 05 December, 2023
Treatment: Use of dasatinib for treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase ph+ cml with resistance or intolerance to prior therapy including imatinib, when administered at ...
Dosage: TABLET;ORAL
PHYRAGO family patents
22. Posimir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11771624 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(16 years from now) | |
| US11400019 | INNOCOLL | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 01, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: To produce post-surgical analgesia
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR family patents
23. Proair Digihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11266796 | TEVA BRANDED PHARM | Inhalation device with integrated electronics |
Feb, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR DIGIHALER family patents
24. Qvar Redihaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583643 | NORTON WATERFORD | Inhalers and related methods |
Aug, 2041
(17 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR REDIHALER family patents
25. Tavneos patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-377) | Oct 07, 2028 |
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2026 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 07 October, 2025
Market Authorisation Date: 07 October, 2021
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
Dosage: CAPSULE;ORAL
TAVNEOS family patents
26. Tlando patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11464735 | ANTARES PHARMA INC | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE;ORAL
TLANDO family patents
27. Tralement patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786548 | AM REGENT | Trace element compositions, methods of making and use |
Jul, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2024 |
Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient
NCE-1 date: 01 May, 2023
Market Authorisation Date: 30 June, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
TRALEMENT family patents
28. Ubrelvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in a patient with severe hepatic impairment
Dosage: TABLET;ORAL
UBRELVY family patents
29. Veklury patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11491169 | GILEAD SCIENCES INC | Remdesivir treatment methods |
May, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg) and for whom concomitant use of chloroquine, or an analog or salt ...
Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS
VEKLURY family patents
30. Vyleesi (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590209 | PALATIN TECHNOLOGIES | Use of bremelanotide in patients with controlled hypertension |
Apr, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 21, 2024 |
Drugs and Companies using BREMELANOTIDE ACETATE ingredient
NCE-1 date: 22 June, 2023
Market Authorisation Date: 21 June, 2019
Treatment: Treating acquired, generalized hypoactive sexual desire disorder (hsdd) in a premenopausal female patient with controlled hypertension by injecting bremelanotide more than once with at least 24 hours ...
Dosage: SOLUTION;SUBCUTANEOUS
VYLEESI (AUTOINJECTOR) family patents
31. Wegovy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2024 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management
Dosage: SOLUTION;SUBCUTANEOUS
WEGOVY family patents
32. Zimhi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571518 | ADAMIS PHARMS CORP | Emergency devices |
Jun, 2041
(17 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syring...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZIMHI family patents
33. Zoryve patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11707454 | ARCUTIS | Topical roflumilast formulation having antifungal properties |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 15 December, 2023
Treatment: Topical treatment of seborrheic dermatitis in patients 9 years of age and older
Dosage: FOAM;TOPICAL
ZORYVE family patents